0001683168-23-002829.txt : 20230501
0001683168-23-002829.hdr.sgml : 20230501
20230501185947
ACCESSION NUMBER: 0001683168-23-002829
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230428
FILED AS OF DATE: 20230501
DATE AS OF CHANGE: 20230501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Downs Christopher
CENTRAL INDEX KEY: 0001705978
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39126
FILM NUMBER: 23875852
MAIL ADDRESS:
STREET 1: 31700 RESEARCH PARK DRIVE
CITY: MADISON HEIGHTS
STATE: MI
ZIP: 48071
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001729427
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822318545
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
BUSINESS PHONE: 1-800-946-9185
MAIL ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
4
1
ownership.xml
X0407
4
2023-04-28
0
0001729427
CNS Pharmaceuticals, Inc.
CNSP
0001705978
Downs Christopher
C/O CNS PHARMACEUTICALS, INC.
2100 WEST LOOP SOUTH, SUITE 900
HOUSTON
TX
77027
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-04-28
4
M
0
521
A
9772
D
Restricted Stock Units
2023-04-28
4
M
0
521
D
Common Stock
521
28248
D
Restricted stock units convert into common stock on a one-for-one basis.
On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
/s/ Christopher Downs
2023-05-01